Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections
Background: Recurrent Urinary Tract Infections (UTIs) in men range from 0.9 to 2.4/1000 individuals in younger men to 7.7/1000 in those over 85, significantly impacting their quality of life. Preventive strategies include autovaccines, but limited evidence exists for males. Methods: A prospective mo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/1/111 |
| _version_ | 1797343149921665024 |
|---|---|
| author | Alexandru Ciudin Bernat Padulles Razvan Popescu Pasqualino Manasia |
| author_facet | Alexandru Ciudin Bernat Padulles Razvan Popescu Pasqualino Manasia |
| author_sort | Alexandru Ciudin |
| collection | DOAJ |
| description | Background: Recurrent Urinary Tract Infections (UTIs) in men range from 0.9 to 2.4/1000 individuals in younger men to 7.7/1000 in those over 85, significantly impacting their quality of life. Preventive strategies include autovaccines, but limited evidence exists for males. Methods: A prospective monocentric, open-label observational study was conducted from August 2018 to August 2021, with follow-up until August 2023 including patients with recurrent UTIs treated with immunotherapy. We evaluated the incidence rate of UTIs per year, the incidence rate of episodes after two or three rounds of the autovaccine, and quality of life measured with the IPSS-QoL questionnaire. Results: A total of 49 patients fulfilled inclusion criteria. The mean age was 72 years (±15), and the median 61. The evolution of UTIs number of episodes after the autovaccine rounds: −37.74% for the first round from 5.3 to 3.3; −33.33% for the second round from 3.3 to 2.2; −45.45% for the third round from 2.2 to 1.2. The mean IPSS score improved from 10.69 to 7.27 after the treatment (32%). The mean QoL subscore enhancement was from 4.22 to 1.92 (54%). With a mean follow-up of 3 years, only nine patients required retreatment. Conclusion: Autovaccine treatment significantly reduced the number of UTI episodes, with a cumulative effect observed after multiple rounds of treatment, demonstrating an enhancement in QoL and with sustained effectiveness and a low need for retreatment. |
| first_indexed | 2024-03-08T10:44:34Z |
| format | Article |
| id | doaj.art-a9c3d72d8409487aa7ee7b70f9e1d7c6 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-08T10:44:34Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-a9c3d72d8409487aa7ee7b70f9e1d7c62024-01-26T17:21:03ZengMDPI AGLife2075-17292024-01-0114111110.3390/life14010111Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract InfectionsAlexandru Ciudin0Bernat Padulles1Razvan Popescu2Pasqualino Manasia3Urology Department, Hospital Universitari de Mollet, 08100 Barcelona, SpainUrology Department, Hospital Universitari de Mollet, 08100 Barcelona, SpainUrology Department, Spitalul Clinic “Prof. Dr. Th. Burghele”, 061344 Bucuresti, RomaniaUrology Department, Hospital Universitari de Mollet, 08100 Barcelona, SpainBackground: Recurrent Urinary Tract Infections (UTIs) in men range from 0.9 to 2.4/1000 individuals in younger men to 7.7/1000 in those over 85, significantly impacting their quality of life. Preventive strategies include autovaccines, but limited evidence exists for males. Methods: A prospective monocentric, open-label observational study was conducted from August 2018 to August 2021, with follow-up until August 2023 including patients with recurrent UTIs treated with immunotherapy. We evaluated the incidence rate of UTIs per year, the incidence rate of episodes after two or three rounds of the autovaccine, and quality of life measured with the IPSS-QoL questionnaire. Results: A total of 49 patients fulfilled inclusion criteria. The mean age was 72 years (±15), and the median 61. The evolution of UTIs number of episodes after the autovaccine rounds: −37.74% for the first round from 5.3 to 3.3; −33.33% for the second round from 3.3 to 2.2; −45.45% for the third round from 2.2 to 1.2. The mean IPSS score improved from 10.69 to 7.27 after the treatment (32%). The mean QoL subscore enhancement was from 4.22 to 1.92 (54%). With a mean follow-up of 3 years, only nine patients required retreatment. Conclusion: Autovaccine treatment significantly reduced the number of UTI episodes, with a cumulative effect observed after multiple rounds of treatment, demonstrating an enhancement in QoL and with sustained effectiveness and a low need for retreatment.https://www.mdpi.com/2075-1729/14/1/111recurrent urinary tract infections (UTIs)autovaccineimmunotherapyquality of life (QoL)incidence rateIPSS |
| spellingShingle | Alexandru Ciudin Bernat Padulles Razvan Popescu Pasqualino Manasia Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections Life recurrent urinary tract infections (UTIs) autovaccine immunotherapy quality of life (QoL) incidence rate IPSS |
| title | Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections |
| title_full | Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections |
| title_fullStr | Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections |
| title_full_unstemmed | Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections |
| title_short | Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections |
| title_sort | autovaccine based immunotherapy a promising approach for male recurrent urinary tract infections |
| topic | recurrent urinary tract infections (UTIs) autovaccine immunotherapy quality of life (QoL) incidence rate IPSS |
| url | https://www.mdpi.com/2075-1729/14/1/111 |
| work_keys_str_mv | AT alexandruciudin autovaccinebasedimmunotherapyapromisingapproachformalerecurrenturinarytractinfections AT bernatpadulles autovaccinebasedimmunotherapyapromisingapproachformalerecurrenturinarytractinfections AT razvanpopescu autovaccinebasedimmunotherapyapromisingapproachformalerecurrenturinarytractinfections AT pasqualinomanasia autovaccinebasedimmunotherapyapromisingapproachformalerecurrenturinarytractinfections |